Key result
Direct TGF-beta(1) inhibition, NAPDH oxidase inhibitors, growth factors, and hormonal treatments may significantly reduce cardiac fibrosis after injury as alternatives to angiotensin II blockade.
Why the study?
Do therapies targeting TGF-beta 1 reduce cardiac fibrosis after injury compared to angiotensin II blockade alone?
Population
In vivo and in vitro models of cardiac injury and fibrosis
Comparison
Therapies targeting TGF-beta 1 vs Angiotensin II blockade alone
Design
Review
Authors
Loading...
These therapies should not yet change practice; leaves open whether direct TGF-β1 inhibition outperforms angiotensin II blockade in reducing fibrosis.
Do therapies targeting TGF-beta 1 reduce cardiac fibrosis after injury compared to angiotensin II blockade alone?
This review highlights emerging therapies targeting TGF-beta 1 as potential alternatives or adjuncts to angiotensin II blockade for preventing post-injury cardiac fibrosis.
Razi Khan (2007) conducted a review in Myocardial Fibrosis. Therapies targeting TGF-beta(1) vs. Angiotensin II blockade was evaluated on Cardiac fibrosis. Direct TGF-beta(1) inhibition, NAPDH oxidase inhibitors, growth factors, and hormonal treatments may significantly reduce cardiac fibrosis after injury as alternatives to angiotensin II blockade.
Synapse has enriched 4 closely related papers on similar clinical questions. Consider them for comparative context: